Antiplatelet Effects of Ticlopidine Are Reduced in Experimental Hypercholesterolemia

Summary

This study determines the antiplatelet effects of oral ticlopidine (100 mg/kg × day) in experimental hypercholesterolemia. Rabbits were fed either a standard diet or a cholesterol-enriched diet (0.5% for 3 months, 1% for 1 month). In normocholesterolemic controls ADP-, but not collagen-induced platelet aggregation was inhibited by ticlopidine treatment. This was accompanied by a significantly enhanced inhibition of ADP-induced platelet aggregation and stimulation of cyclic AMP accumulation by iloprost. Hypercholesterolemia considerably attenuated the inhibition of ADP-induced aggregation by ticlopidine but did not change its effect on the iloprost-induced inhibition of platelet function and cyclic AMP formation. ADP-induced platelet-derived Llnumbuxane formation was considerably greater in hypercholesterolemic rabbits and not reduced by ticlopidine. Ticlopidine did also not significantly influence the extent and severity of atherosclerotic plaque formation although a tendency for improvement was observed in a subgroup of animals. The data suggest that hypercholesterolemia attenuates the inhibitory effect of ticlopidine on A DP-induced platelet aggregation. This might be related to the stimulation of thromboxane formation by ADP in hypercholesterolemia. The maintained protection from ADP-induced inhibition of cAMP accumulation suggests a minor role of this mechanism in the progression of hypercholesterolemia-induced vessel disease in this model.

• References

• 1 Carvalho AC A, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8
• 2 Schrör K. Platelet reactivity and arachidonic acid metabolism in type IJ hyperlipoproteinemia and its modification by cholesterol-lowering agents. Eicosanoids 1990; 3: 67-72
• 3 Croft DK, Beilin LJ, Vandongen R, Rouse I, Masarei J. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolemia. Atherosclerosis 1990; 83: 101-9
• 4 Ross R. The pathogenesis of atherosclerosis – An update. N Engl J Med 1986; 314: 488-500
• 5 Curtiss LK, Black AS, Takagi Y, Plow EF. New mechanism for foam cell generation in atherosclerotic lesions. J Clin Invest 1987; 80: 367-73
• 6 Moore S, Friedman RJ, Singal DP, Gauldie J, Blajchman MA, Roberts RS. Inhibition of injury-induced thromboatherosclerotic lesions by antiplatelet serum in rabbits. Thromb Haemost 1976; 35: 70-81
• 7 Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and atherosclerosis in baboons. Circ Res 1983; 53: 731-9
• 8 Kristcnsen SD, Roberts KM, Kishk YT, Martin JF. Accelerated atherogenesis occurs following platelet destruction and increases in mcgacaryocytc size and DNA content. Eur J Clin Invest 1990; 20: 239-47
• 9 Bailey JM, Makheja AN, Butler J, Salata K. Antiinflammatory drugs in experimental atherosclerosis. Atherosclerosis 1979; 32: 195-203
• 10 Jouve R, Juhan-Vague I, Aillaud M-F, Sermcnt-Jouve M-P, Payan H. Comparison of the effects of aspirin and indomcthacin on aortic atherogenesis induced in rabbits. Atherosclerosis 1982; 42: 319-22
• 11 Chyattc D, Chen TL. Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease. Neurosurgery 1990; 26: 565-9
• 12 Sun Y-P, Zhu B-Q, Sievers RE, Isenberg WM, Parmley WW. Aspirin inhibits platelet activity but does not attenuate experimental atherosclerosis. Am Heart J 1993; 125: 79-86
• 13 Debons AF, Fani K, Jimenez FA. Enhancement of experimental atherosclerosis by aspirin. J Toxicol Environ Health 1981; 8: 899-906
• 14 Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Heliums JD. Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF-multimcrs, requires adenosine diphosphate, and resistant to aspirin. Blood 1988; 71: 1366-74
• 15 Rajagopalan S, Mc Intyre LV, Hall ER, Wu KK. The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic forces. Biochim Biophys Acta 1988; 958: 108-15
• 16 Defrcyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: A review. Semin Thromb Hemost 1989; 15: 159-66
• 17 Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: 252-61
• 18 Samama ChM, Bonnin Ph, Bonneau M, Pignaud G, Mazoyer E, Baillart O, Maffrand JP, Viars P, Caen JP, Drouet LO. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the mg. Thromb Haemost 1992; 68: 500-5
• 19 Defrcyn G, Gachet C, Savi P, Driot F, Cazcnavc JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE₁-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-90
• 20 Reece AH, Walton PL. Inhibition of intimal proliferation of rabbit aorta by ticlopidine (Abstract 0873). Thromb Haemost 1979; 42: 367
• 21 Friedman RJ, Stcmerman MB, Wenz B, Moore S, Gauldie J, Gent M, Tiell ML, Spaet TH. The effect of thrombocytopenia on experimental atherosclerotic lesion formation in rabbits. J Clin Invest 1977; 60: 1191-201
• 22 Löbel P, Schrör K. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits. Atherosclerosis 1989; 80: 69-79
• 23 Weber A-A, Hohlfcld Th, Strobach H, Schror K. Oral naftidrofurvl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemia. J Cardiovasc Pharmacol 1993; 21: 332-8
• 24 Schror K, Seidel H. Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn Schmiedeberg’s Arch Pharmacol 1988; 337: 177-82
• 25 Cristalli G, Mills DC B. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem J 1993; 291: 875-81
• 26 Hass WK, Easton JD, Adams jr HP, Prysc-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
• 27 Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32
• 28 Hohlfeld Th, Weber A, Schror K. Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia. In: Prostaglandins in the cardiovascular system. Sinzinger H, Schror K. (eds) Basel: Birkhauser; Agents Actions 1992. (; 37). (Suppl) 289-96
• 29 Martin JF, Slater DN, Kishk YT, Trowbridge EA. Platelet and megakaryocyte changes in cholesterol-induced experimental atherosclerosis. Arteriosclerosis 1985; 5: 604-12
• 30 Weber A, Hohlfeld Th, Schror K. ADP-induced second wave aggregation in platelet rich plasma from hypercholesterolemic rabbits. Thromb Res 1991; 64: 703-12
• 31 Dalai KB, Ebbe S, Mazoyer E, Carpenter D, Yee T. Biochemical and functional abnormalities in hypercholesterolemic rabbit platelets. Lipids 1990; 25: 86-92
• 32 Sweatt DJ, Blair IA, Cragoe EJ, Limbird LE. Inhibitors of Na⁺/H⁺ exchange block epinephrine- and ADP-induced stimulation of human platelet phospholipase C by blockade of arachidonic acid release at a prior step. J Biol Chem 1986; 261: 8660-6
• 33 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A₂ causes feedback amplification involving extensive thromboxane A ₂formation upon close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-51
• 34 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregation agents. Thromb Haemost 1989; 62: 968-76
• 35 Sage SO, Heemskerk JW M. Thromboxane receptor stimulation inhibits adenylate cyclase and reduces cyclic AMP-mediated inhibition of ADP-evoked responses in fura-2-loaded human platelets. FEBS Lett 1992; 298: 199-202